Our annual Biobusiness Summer School is one of our most well established activities throughout the year. The first Biobusiness Summer School was held in 2014 and the event has only gained more popularity ever since. Each year, Synapse - Life Science Connect invites 50 ambitious and motivated students and recent graduates from numerous countries to participate. The summer school is a 5 day activity where industry experts within various fields such as marketing, regulatory affairs, finance accounting, intellectual property rights, consulting, strategy implementation, bio-entrepreneurship and much more come to share their knowledge and expertise. 

► International Property Rights
► Business Development
► Regulatory Affairs
► Bioentrepreneurship
► Consulting
► Venture Capital
► Innovation
► Case solving
► Inspiration and insight from start-up to major company
► Detailed programme will be announced at a later time

Alongside the workshops and talks there will be a case competition developed and run by the Boston Consulting Group and BioInnovation Institute.



Orphazyme was founded in Denmark in 2009 based on a scientific discovery about the role of heat shock proteins (HSPs), which was described in a well-cited article published in the journal Nature. One of the lead authors of that paper, Thomas Kirkegaard Jensen, is a founder of our company and our Chief Scientific Officer.

Today, we have translated that scientific discovery into a late-stage clinical development program. We are working to obtain regulatory approvals that will allow us to bring a novel treatment to patients, applying our knowledge of heat shock proteins (HSPs) for the benefit of people living with rare neurodegenerative diseases.

BioInnovation Institute

BII offers entrepreneurially-minded researchers or anyone with a research-based idea help to bring interdisciplinary ideas to life and research to market. We offer state-of-the-art facilities and various funding opportunities, as well as partnerships and programs with technical, scientific and commercial experts.

Our main focus is health tech, bio-industrials and therapeutics. We envision that strong collaborations, a passion for science, and an open mind will foster research-based innovation and viable start-ups. BII does not work for profit but for the benefit of human welfare and society around the globe.

BII is a Novo Nordisk Foundation initiative. In the first three years of operation, until the end of 2020, BII has been granted DKK 392 million. After this establishment phase has been evaluated, the Novo Nordisk Foundation’s Board of Directors will decide whether to establish BII as an independent foundation and grant funding for the next seven years of operation.

Venture Cup

Venture Cup Denmark is an association of all the Danish universities (except RUC). We work to promote and showcase entrepreneurship among university students, and help eliminate the gap between the academic world and the business community. A pioneer in the field, Venture Cup has been founded in 2000 as one of the first entrepreneurial organisations in the country.

We host two national startup competitions annually, a University Startup World Cup with teams from all over the world and access to a large network of Venture Cup Experts. Early 2018 we have launched the program Nordic HealthTech Talents with the support of Novo Nordisk Foundation.

Besides that we’re always trying to be in the loop and cooperate with companies and stakeholders if we believe it supports our mission of inspiring and showcasing the university students.

Lundbeckfonden Ventures

Lundbeckfonden Ventures is an evergreen venture fund investing internationally in life science companies. Our focus is primarily projects and companies with development candidates close to or in clinical development. We are particularly interested in speciality pharma product opportunities and in technology platforms that have demonstrated their value in generating development candidates.

About us
Since 2009, we have invested in 31 companies in USA and Europe and have an active portfolio of around 20 companies representing a broad spectrum of therapeutic fields. Annually we invest 350 to 400 million Danish kroner.
We work internationally and as lead investor when investing in Europe. We are determined to add value to our investments and will involve ourselves actively in our portfolio companies and work in close collaboration with their management and boards.


We are the CRISPR Microbiome Company

Precision killing of bacteria has the impact to revolutionise the management of untreatable and difficult-to-treat infections as well as complex diseases directly impacted by the human microbiota.

Our mission is to develop CRISPR-based medicines that give hope for effective and safe treatment of difficult-to-treat diseases in the future.


We are passionate people building winning teams with our customers. With deep roots in the pharmaceutical industry, we supply services that meet the highest requirements for quality, security and standardization. Read more about our quality and security​.

NNIT​ is one of Denmark’s leading consultancies in IT development, implementation and operations. For over a decade, we have applied the latest advances in technology to make software development, business processes and communication significantly more effective. Read about our values and culture​​​.

​NNIT’s service offerings include advising, building, implementing, managing and supporting IT solutions and operating IT systems for customers. ​In 2018 our revenue stood at DKK 3 billion. Read more about our life sciences services​ and customers​​.

Today, NNIT has approximately 3,300 employees – of which approximately half work outside the borders of ​Denmark – in China​​, the Czech Republic​, the ​Philippines​, Switzerland​, Germany and in the US. Read about our ​history here.​​​

Eir Ventures

Eir Ventures is a life sciences venture capital fund investing in private companies with stellar entrepreneurs developing transformative therapeutic approaches. Optimal and responsible value creation for companies and investors is obtained by working closely with our portfolio companies. We contribute our company building and management expertise, strategic thinking and our extensive networks to drive healthcare innovation to the benefit of patients, healthcare systems, investors and society.

The Eir Ventures team has a truly international experience base and we have committed our entire professional lives to impacting people’s health by engaging in innovative medicine that has the potential to prevent, cure or alleviate disease.

We believe that the Nordics represents a unique investment opportunity with high return potential due to an imbalance between the abundance of medical innovation and the scarcity of professional capital.

The Fund takes its name from the goddess Eir, who in old norse mythology was the goddess of health, well-being and medicine.

Eir Ventures is backed by leading local and international institutional investors and, uniquely,  by leading Nordic universities.


HØIBERG is a full service patent law firm located in Denmark, which is providing services within the fields of Intellectual Property Rights (IPR), including patents, designs, innovation management, technology transfer and business development. HØIBERG provides expert IPR knowledge in the fields ranging from biotech, medtech, nanotech, chemistry and cleantech to software, electronics and mechanics.


Horten is a full-service law firm with more than 60 years’ experience and 320 employees, which is specialised within sectors characterised by strict regulation or where technological development and innovative approaches are fundamental – such as energy and supply, Life Science and Healthcare, IT, technology and media as well as the public sector.
We use our special expertise within regulated areas proactively to solve complex problems and think innovatively, be it new energy forms, advanced technology or cooperation between public and private parties.

LEO Pharma

Leo Pharma is an independent, research-based pharmaceutical company. The company develops, manufactures and markets pharmaceutical drugs to dermatologic and thrombotic patients in more than 100 countries globally.

To realise their vision of becoming the preferred dermatology care partner improving people’s lives around the world, they are expanding into new regions and markets, reaching more patients and societies with drugs and therapies that address unmet medical needs.

Leo Pharma has its own sales forces in 61 countries and employs around 5,000 employees worldwide. The company is headquartered in Denmark and is wholly owned by the Leo Foundation.


Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125 000 people of more than 140 nationalities work at Novartis around the world.

Forward Pharma

Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on Biogen’s net sales of Tecfidera® or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the ‘355 Patent Opposition Proceeding, including any appeal thereto.


Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.

An estimated 700 million people worldwide are living with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases – we call this Progress in Mind.

Despite the challenges, Lundbeck remains steadfast in our commitment to deliver innovation that patients need. We work tirelessly to advance neuroscience, develop new and innovative treatments, and support patient communities – all with the aim of restoring brain health and transforming the lives of the millions of people living with a brain disease. Not only does the burden of brain diseases demand action now, it also demands expertise and courage. We know that to get radically different results, we need to pursue radically different approaches.

Our approximately 5,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing, and sales. Our pipeline consists of several R&D programs and our products are available in more than 100 countries. We have research centers in Denmark and California and our production facilities are located in Denmark, France, and Italy.

Boston Consulting Group

The Boston Consulting Group (BCG) is a global management consulting firm and the world’s leading advisor on business strategy. Now in our sixth decade, we continue not only to grow but also to embody the same timeless sense of purpose and the constant call for renewal that our founder Bruce Henderson instilled at our inception. Our mission is clear. We go deep to unlock insight and have the courage to act. We bring the right people together to challenge established thinking and drive transformation. We work with our clients to build the capabilities that enable organizations to achieve sustainable advantage. We are shaping the future.

Ward 24|7

Current manual monitoring practice outside the ICU doesn’t reveal clinical deterioration

Current monitoring of vital signs (blood pressure, respiratory rate, oxygen saturation etc.) is insufficient

Major surgery and acute medical disease entail substantial risk of complications and death

Manual monitoring is too infrequent to detect clinical deterioration

Manual data interpretation cannot capture trends and combination of several physiological parameters


Founded in 2008, we are a privately-held biotech company with two primary areas of business: Pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs.

Our focus is the metabolic space (obesity, diabetes, NASH and diabetic complications) where we specialize in in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, 3D imaging, stereology, NGS (next generation sequencing), bioinformatics and ex vivo assays.

We work with some of the most interesting and loyal partners and customers from across the world within big pharma, biotech and academia. Through a constant focus on high quality, scientific excellence, speed and solid teamwork, we have established ourselves as a highly professional and competent partner in the market.


Our name, Adcendo, reflects this strategy of targeting ADCs to specialized endocytic receptors.

Our first target, uPARAP/endo180, reflects these characteristics, providing an efficient entry point for an ADC type drug into target-positive cancer cells, working essentially as a drug internalization pump to further enhance a targeted effect.

Adcendo was founded in 2017 as a spin-out from The University of Copenhagen and Rigshospitalet by scientists Niels Behrendt, Lars Henning Engelholm and Christoffer Nielsen from The Finsen Laboratory, together with biotech entrepreneur Henrik Stage.

Adcendo has been part of BioInnovation Institute’s Creation House Program from mid 2019 until closing of series A financing in April 2021.

Novo Nordisk Regulatory Affairs

In Novo Nordisk, Regulatory Affairs secure the approval of new multi-billion dollar products and drug indications, making it possible for the company to bring innovative products to patients. The department stand at the centre of project planning and execution from the earliest stages of drug development all the way through life cycle management. A close collaboration with scientists to ensure new ideas will turn into successful products, thus a large part of Regulatory Affairs is based on the ability to understand the science behind.
The Regulatory Affairs graduate programme has been designed to develop top talents into becoming future leaders within this area. The Graduate Program is a two-year program consisting of three department rotations in which one of these will take place in one of the global affiliates. The Programme is open to applicants from all over the world who have recently acquired a degree from the life sciences such as pharmacy, chemical engineering, biology, biotechnology biomedicine or a related field.

Innovation Fund Denmark

We invest in sustainable solutions

Innovation Fund Denmark creates a framework for entrepreneurs, researchers and businesses so they can develop innovative and viable solutions to society’s challenges.

For example new climate mitigating solutions, healthier food, a more effective health care, cleaner environment, green transport, start-up journeys – and much more.

We want to create real value from our investments

It is important that the Danish society benefits as much as possible from the money Innovation Fund Denmark invests in research and investment. That is why we prioritize responsibility highly. All projects we invest in have requirements of societal engagement, transparency, education and ethics.

Compared to other investors Innovation Fund Denmark’s results do not necessarily need to be seen in share prices or end of year financial results. Innovation Fund Denmark’s results must also be evaluated on social welfare improvements, increased societal wealth, jobs, reduction of CO2 emissions, cleaner environment etc.

We are ready to take a chance

Innovation Fund Denmark is ready to take a chance in a project, even though others may not be able to see the possibilities in it. Innovation Fund Denmark was created to invest in projects with high risk – and also high potential. And we do this in an easy, simple and transparent way – with as little bureaucracy as possible.

We are all of Denmark’s investment fund

Innovation Fund Denmark was created to strengthen and foster strategic research and innovation projects in all of Denmark. That is why the Fund has offices spread all over the country in Copenhagen, Aarhus, Odense and Aalborg.


Chromologics is a Danish biotech spin-out from the Technical University of Denmark. We have developed a fungal biotech platform for the production of novel, natural colorants.

Our proprietary fermentation process allows us to be first movers to introduce lab-grown food colorants to the market. Our production is sustainable, scalable and cost-competitive. Unlike other existing natural colors, our colorants are not extracted from high value raw materials like fruit and vegetables, but produced by our wild type cell factory. Our fungal strains are non-GMO and our pigments are compatible with most dietary needs, including kosher, halal, and vegan diets.

Sustainable colors made by nature.

BOOST Pharma

BOOST Pharma is based on years of collaborative research from Karolinska Institute in Stockholm with the focus on novel cell therapy treatments for Osteogenesis Imperfecta. The research teams of associate professor Cecilia Götherström and professor Magnus Westgren have shown that that treatment with BOOST Cells greatly enhanced the quality of life for patients suffering from this otherwise extremely debilitating disease.

Trailhead Biosystems

Trailhed Biosystems are the pioneer of HD-DoE™ (High-Dimensional Design of Experiments) technology. Our platform merges developmental biology and cell therapeutics with cutting-edge hardware, computerized experimental design, and analysis to perform process-specific parameter optimization in the development of cell therapies.


Date: 8th – 12th of August, 2022

Location: Blegdamsvej 3B, 2200 København (Faculty Club, Panum)

Entry/Admission requirements: Open for all students, recent graduates, PhD or post-docs within life sciences.

Application deadline: June 17th

We will notify selected applicants within two weeks after application period has ended. 


In order for an application to be eligible you must include the following:

  • CV (PDF)
  • Screenshot of your 16-personality test result (test can be taken HERE). Please note, that we need a screenshot of the TEST RESULT, not just the personality type.
  • 1 page motivational letter, where you address the following:
    • Your motivation for participating in the BioBusiness Summer School
    • What can you bring to the team work, and what do you hope to learn during the week?
    • How does your personality type (result from test) align with yourself, and does it resonate with what you will be bringing to the summer school?

If above criteria are not met your application will be disregarded. 

16-personalities test

In order to ensure the best possible team-formations during the week we are focusing on personality types in this years applications. You can take the test by following this link: 

Please address questions to afg@synapse-connect.org